NF-kappaB in carcinoma therapy and prevention

Expert Opin Ther Targets. 2008 Sep;12(9):1109-22. doi: 10.1517/14728222.12.9.1109.


Background: NF-kappaB includes a family of signal-activated transcription factors that normally regulate responses to injury and infection but which are aberrantly activated in many carcinomas.

Objective: To review the activation and role of NF-kappaB in pathogenesis and as a target for treatment and prevention in carcinoma.

Methods: Evidence from experimental, epidemiological, preclinical studies and clinical trials cited in the literature are reviewed.

Results/conclusion: Cumulative evidence implicates NF-kappaB in cell survival, inflammation, angiogenesis, spread and therapeutic resistance during tumor development, progression and metastasis of carcinomas. Non-specific natural and synthetic agents that inhibit NF-kappaB have demonstrated activity and safety in prevention or therapy. NF-kappaB-activating kinases and the proteasome are under investigation for targeted prevention and therapy of carcinoma.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Carcinoma / drug therapy*
  • Carcinoma / metabolism*
  • Humans
  • Mice
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / metabolism*


  • Antineoplastic Agents
  • NF-kappa B